## HPI
Patient with ER+/HER2- early-stage breast cancer on adjuvant therapy.

## Assessment and Plan
Continue endocrine therapy per guidelines; consider genomic test if recurrence risk unclear.

## Pathology
Invasive ductal carcinoma, ER+, PR+, HER2-, Ki-67 low.
